Cell Therapeutics Granted Pixantrone Orphan Drug Designation by EMEA for DLBCL

Monday, Cell Therapeutics Inc. said it has been granted pixantrone orphan drug designation by European Medicines Agency or EMEA for the treatment of [diffuse large B-cell lymphoma] DLBCL which accounts for around 80% of aggressive non-Hodgkin’s lymphoma.
RTTNews